Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [119].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“there was no significant difference in the 5-year survival rate”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group.”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Hyams, D. M., Mamounas, E. P., Petrelli, N., Rockette, H., Jones, J., Wieand, S. H., Deutsch, M., Wickerham, L. D., Fisher, B., & Wolmark, N. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02054976 · Cited by 360
Research works printed but not linked: 3
- Seegenschmiedt MH, 1993, Strahlenther Onkol, 169, 83
- Pichlmaier H, 1994, Chirurg, 65, 411
- Hermanek P. What can the pathologist tell the surgeon about rectal cancer resection? In: Scholefield JH, ed. Challenges in colorectal cancer. Oxford, England: Blackwell, 2000:81-90.
Cited by
Items 701–800 of 1,004
Lymph Node Retrieval after Preoperative Chemoradiotherapy for Rectal Cancer
Damin, D. C., Rosito, M. A., Contu, P. D. C., Tarta, C., Ferreira, P. R. F., Kliemann, L. M., & Schwartsmann, G. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-1916-4 · Cited by 67
Sakamoto, J., Hamada, C., Yoshida, S., Kodaira, S., Yasutomi, M., Kato, T., Oba, K., Nakazato, H., Saji, S., & Ohashi, Y. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603686 · Cited by 68
“As compared with postoperative chemoradiotherapy, preoperative chemoradiotherapy does not improve OS, but inhibits local recurrence and reduces toxicity (Sauer et al, 2004).”
Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer
Bouvier, A., Jooste, V., Bonnetain, F., Cottet, V., Bizollon, M.-H., Bernard, M., & Faivre, J. (2008) · Cancer · doi:10.1002/cncr.23629 · Cited by 68
Rao, S., Zeng, M.-S., Xu, J.-M., Qin, X.-Y., 陈财忠, Li, R.-C., & Hou, Y. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i30.4141 · Cited by 67
“over postoperative chemoradiotherapy [ 9 ,10]”
BackgroundArmstrong, D. E., Raissouni, S. S., Hiller, J. A. P., Mercer, J., Powell, E. D., MacLean, A. R., Jiang, D., Doll, C., Goodwin, R. A., Batuyong, E., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.06.001 · Cited by 70
Zitt, M., Müller, H. M., Rochel, M., Schwendinger, V., Zitt, M., Goebel, G., DeVries, A., Margreiter, R., Oberwalder, M., Zeillinger, R., et al. (2008) · Disease Markers · doi:10.1155/2008/598071 · Cited by 74
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., & Barni, S. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.03 · Cited by 69
“Results Following the systematic literature review, a total of 9,012 publications were analyzed (Figure 1), with 22 studies, published between 1999 and 2015, considered for inclusion in the final analyses (2,21-42).”
BackgroundGérard, J., Rostom, Y., Gal, J., Benchimol, D., Ortholan, C., Aschele, C., & Hannoun‐Lévi, J. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.02.001 · Cited by 76
“[7] Sauer R, Becker H, Hohenberger W, et al.”
BackgroundInfluentialJang, B., Chang, J. H., Chie, E. K., Kim, K., Park, J. W., Kim, M. J., Song, E., Nam, Y., Kang, S. W., Jeong, S., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.04.015 · Cited by 74
Maizlin, Z. V., Brown, J. A., So, G., Brown, C. J., Phang, P. T., Walker, M. L., Kirby, J. M., Vora, P., & Tiwari, P. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181c5321e · Cited by 66
The Quality-of-Life Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Herman, J. M., Narang, A. K., Griffith, K. A., Zalupski, M. M., Reese, J. B., Gearhart, S. L., Azad, N. S., Chan, J., Olsen, L., Efron, J. E., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.09.006 · Cited by 70
de Campos‐Lobato, L. F., Stocchi, L., Dietz, D. W., Lavery, I. C., Fazio, V. W., & Kalady, M. F. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e318221eb64 · Cited by 66
Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression
Choi, S., & Ku, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.060 · Cited by 72
Jang, N. Y., Kang, S., Kim, D., Kim, J. H., Lee, K., Kim, I. A., & Js, K. (2011) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181fcee68 · Cited by 69
Elevated preoperative CEA is associated with worse survival in stage I–III rectal cancer patients
Tarantino, I., Warschkow, R., Worni, M., Merati‐Kashani, K., Köberle, D., Schmied, B. M., Müller, S., Steffen, T., Cerny, T., & Güller, U. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.267 · Cited by 66
“The indication for adjuvant treatment was based on the initial clinical stage (before the start of neoadjuvant radiochemotherapy), not on the final pathological disease stage (Sauer et al, 2004).”
BackgroundMethodMant, D., Gray, A. M., Pugh, S. A., Campbell, H., George, S., Fuller, A., Shinkins, B., Corkhill, A., Mellor, J., Dixon, E. L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21320 · Cited by 71
CT-based Radiomics Signature to Discriminate High-grade From Low-grade Colorectal Adenocarcinoma
Huang, X., Cheng, Z., Huang, Y., Liang, C., He, L., Ma, Z., Chen, X., Wu, X., Li, Y., Liang, C., et al. (2018) · Academic Radiology · doi:10.1016/j.acra.2018.01.020 · Cited by 69
“Preoperatively, radiotherapy or chemoradiotherapy could improve local control and disease-free survival in high-risk patients with rectal cancers (11,12).”
BackgroundJia, H., Shen, X., Guan, Y., Xu, M., Tu, J., Mo, M., Xie, L., Yuan, J., Zhang, Z., Cai, S., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.06.022 · Cited by 70
Preoperative Stereotactic Radiosurgery for Brain Metastases
Routman, D. M., Yan, E., Vora, S. A., Peterson, J., Mahajan, A., Chaichana, K. L., Laack, N. N., Brown, P. D., Parney, I. F., Burns, T. C., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00959 · Cited by 67
“For example, the German rectal cancer study group reported results of a randomized trial which showed improved outcomes including better local control and less grade 3 or 4 toxicity with receipt of preoperative as compared to postoperative radiotherapy (16).”
BackgroundSong, C., Chung, J.-H., Kang, S., Kim, D., Oh, H., Lee, H. S., Kim, J. W., Lee, K., Kim, J. H., & Kim, J. H. (2018) · Cancers · doi:10.3390/cancers10090319 · Cited by 65
“However, pCR is present in only 8–20% of patients [1,11], raising the question as to whether a more precise stratification with TRGs could serve as a prognostic factor for a wider range of patients.”
Traverso, A., Kazmierski, M., Shi, Z., Kalendralis, P., Welch, M. L., Nissen, H. D., Jaffray, D. A., Dekker, A. L. A. J., & Wee, L. (2019) · Physica Medica · doi:10.1016/j.ejmp.2019.04.009 · Cited by 73
An, X., Lin, X., Wang, F.-H., Goodman, K. A., Cai, P., Kong, L.-H., Fang, Y., Gao, Y., Lin, J., Wan, D.-S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.026 · Cited by 69
Engels, B., Platteaux, N., den Begin, R. V., Gevaert, T., Sermeus, A. B. L., Storme, G. A., Verellen, D., & Ridder, M. D. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.10.026 · Cited by 70
“The 5-year PFS and OS of 57% and 68% in our study are in line with the 5-year PFS and OS results after preoperative CRT, which are within the range of 56–68% and 66–76%, respectively [5–7].”
BackgroundMethodResultInfluentialKim, S. Y., Hong, Y. S., Kim, D. Y., Kim, T. W., Kim, J. H., Im, S.-A., Lee, K. S., Yun, T., Jeong, S., Choi, H. S., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.035 · Cited by 66
“Further trials are warranted to investigate predictive bio- markers, appropriate partner chemotherapy, and the right se- quence with radiotherapy for the optimal use of cetuximab with preoperative CRT in the treatment of patients with LARC.”
BackgroundMethodInfluentialToiyama, Y., Inoue, Y., Saigusa, S., Kawamura, M., Kawamoto, A., Okugawa, Y., Hiro, J., Tanaka, K., Mohri, Y., & Kusunoki, M. (2013) · PubMed · Cited by 66
Matsuda, T., Sumi, Y., Yamashita, K., Hasegawa, H., Yamamoto, M., Matsuda, Y., Kanaji, S., Oshikiri, T., Nakamura, T., Suzuki, S., et al. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-2974-1 · Cited by 67
de Jongh, S. J., Tjalma, J. J. J., Koller, M., Linssen, M. D., Vonk, J., Dobosz, M., Jorritsma, A., Kleibeuker, J. H., Hospers, G. A. P., Havenga, K., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.232355 · Cited by 67
Gill, S., Blackstock, A. W., & Goldberg, R. M. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60974-9 · Cited by 74
Sun, H., Xu, Y., Song, A., Shi, K., & Wang, W. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.17.18342 · Cited by 64
Effects of exercise therapy in cancer patients undergoing radiotherapy treatment: a narrative review
Piraux, E., Caty, G. D., Nana, F. A., & Reychler, G. (2020) · SAGE Open Medicine · doi:10.1177/2050312120922657 · Cited by 73
Kang, S., Cho, J. R., Jeong, S., Oh, J. H., Ahn, S., Choi, S., Kim, D., Lee, B. H., Youk, E. G., Park, S. C., et al. (2020) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2020.100087 · Cited by 64
“The current preoperative chemoradiotherapy or rectal cancer increases the stoma-free rate [5] , improves herapeutic compliance, and reduces local recurrence [6] .”
Agostini, M., Zangrando, A., Pastrello, C., D’Angelo, E., Romano, G., Giovannoni, R., Giordan, M., Maretto, I., Bedin, C., Zanon, C., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1046652 · Cited by 72
SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression
Findlay, V. J., Wang, C., Nogueira, L. M., Hurst, K. E., Quirk, D. M., Ethier, S. P., O'Carroll, K. F. S., Watson, D. K., & Camp, E. R. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0207 · Cited by 65
“5-Fluorouracil (5FU)-based neoadjuvant chemoradiation therapy has become standard care for patients with advanced rectal cancer, resulting in decreased local recurrence rates, improved tolerance of prescribed therapy, improved organ preservation, and fewer treatment-related complications (1).”
Kleiman, A., Alkhamis, A., Farsi, A., Kezouh, A., Vuong, T., Gordon, P. H., Vasilevsky, C., Morin, N. A., Faria, J., Ghitulescu, G. A., et al. (2015) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-015-2814-3 · Cited by 64
Märkl, B., Kerwel, T. G., Wagner, T., Anthuber, M., & Arnholdt, H. (2007) · Modern Pathology · doi:10.1038/modpathol.3800824 · Cited by 66
Wolff, R. A., Varadhachary, G. R., & Evans, D. B. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0002-3 · Cited by 65
Long-term Results of Rectal Cancer Surgery with a Systematical Operative Approach
Lange, M. M., Martz, J. E., Ramdeen, B., Brooks, V. L., Boachie‐Adjei, K., van de Velde, C. J. �., & Enker, W. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2832-2 · Cited by 70
Dekker, J. W. T., Peeters, K. C. M. J., Putter, H., Vahrmeijer, A. L., & van de Velde, C. J. �. (2010) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2010.09.007 · Cited by 69
“Int J Radiat Oncol Biol Phys 2003; 55(5): 1311-20.”
BackgroundInfluentialValentini, V., van Stiphout, R. G. P. M., Lammering, G., Gambacorta, M. A., Barba, M. C., Bębenek, M., Bonnetain, F., Bosset, J.-F., Bujko, K., Cionini, L., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.001 · Cited by 67
“This included the EORTC trial [8] comparing preoperative radiotherapy with preoperative chemoradiation and observation with postoperative chemotherapy in a 2 2 factorial design, the French trial [9] comparing preoperative radiotherapy with preoperative chemoradiation, the German trial [10] comparing preoperative chemo…”
Self-citationWolff, H. A., Wagner, D. M., Conradi, L., Hennies, S., Ghadimi, M. B., Hess, C. F., & Christiansen, H. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.10.018 · Cited by 64
“Since the German Rectal Cancer Study Group and others [3–6] showed that preoperative radiochemotherapy improves locoregional tumor control as compared to postoperative radiochemotherapy (RCT), this preoperative multimodal setting became standard in treatment of rectal cancer stage II and III Union Internationale Contr…”
BackgroundSelf-citationYang, J. T., Oh, J. H., Apte, A., Son, C. H., Deasy, J. O., & Goodman, K. A. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.09.002 · Cited by 65
“Acute hematologic toxicity associated with pelvic RT with continuous infusion 5-FU for rectal cancer has been reported up to 8% [5,19–22], and pelvic RT with capecitabine was found to cause less HT in a randomized phase III trial comparing oral capecitabine and intravenous 5-FU chemotherapy (2% vs.”
BackgroundMethodConcomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer
Haas-Kock, D. F. D., Buijsen, J., Pijls-Johannesma, M. C. G., Lutgens, L. C. H. W., Lammering, G., van Mastrigt, G. A. P. G., Ruysscher, D. D., Lambin, P., & van der Zee, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006269.pub2 · Cited by 68
Kim, S. Y., Joo, J., Kim, T. W., Hong, Y. S., Kim, J. E., Hwang, I. G., Kim, B. G., Lee, K., Kim, J., Oh, H.-S., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.04.013 · Cited by 68
Burton, S., Brown, G. M., Daniels, I. R., Norman, A. R., Swift, I. R., Abulafi, M., Wotherspoon, A., & Tait, D. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.12.027 · Cited by 65
Ng, S. S. M., Lee, J. F. Y., Yiu, R. Y. C., Li, J. C. M., Hon, S. S. F., Mak, T. W. C., Leung, W. W., & Leung, K. L. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31828fe119 · Cited by 69
Levine, R. A., Chawla, B. K., Bergeron, S., & Wasvary, H. J. (2012) · International Journal of Colorectal Disease · doi:10.1007/s00384-012-1501-z · Cited by 63
“Neoadjuvant therapy has resulted in lower recurrence rates [35] and improved disease-free survival [36] in large randomized trials.”
BackgroundManagement of Locally Advanced Primary and Recurrent Rectal Cancer
de Wilt, J. H. W., Vermaas, M., Ferenschild, F. T. J., & Verhoef, C. K. (2007) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-2007-984870 · Cited by 67
“A recent German trial has demonstrated the benefits of preoperative CRT with improved compliance, reduced toxicity, and increased local control.(13) In many European centers, radiotherapy only was used as neoadjuvant treatment for locally advanced rectal cancer,(14) but the addition of chemotherapy has recently been d…”
Radiotherapy and "new" drugs-new side effects?
Niyazi, M., Maihöfer, C., Krause, M., Rödel, C. M., Budach, W., & Belka, C. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-177 · Cited by 69
“the classical CAO/ARO/AIO-94 trial [37].”
Self-citationCarlomagno, C., Farella, A., Bucci, L., D’Armiento, F. P., Pesce, G., Pepe, S., Cannella, L., Pacelli, R., Stefano, A. D., Solla, R., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn719 · Cited by 63
Dudani, S., Marginean, H., Tang, P. A., Monzon, J. G., Raissouni, S. S., Asmis, T. R., Goodwin, R. A., Gotfrit, J., Cheung, W. Y., & Vickers, M. M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5892-x · Cited by 72
Glimelius, B. L. G., Beets‐Tan, R. G. H., Blomqvist, L., Brown, G. M., Nagtegaal, I. D., Påhlman, L., Quirke, P., Valentini, V., & van de Velde, C. J. �. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4473 · Cited by 67
Early and Late Toxicity of Radiotherapy for Rectal Cancer
Joye, I., & Haustermans, K. M. (2014) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-08060-4_13 · Cited by 74
Rosenberg, R., Nekarda, H., Zimmermann, F. B., Becker, K., Lordick, F., Höfler, H., Molls, M., & Siewert, J. R. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20844 · Cited by 64
“motherapy improved the local recurrence rate significantly compared to postoperative radiochemotherapy [3].”
BackgroundInfluentialAyez, N., Burger, J. W. A., van der Pool, A. E., Eggermont, A. M. M., Grünhagen, D. J., de Wilt, J. H. W., & Verhoef, C. K. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e318279b743 · Cited by 65
Tsai, C. J., Crane, C. H., Skibber, J. M., Rodríguez-Bigas, M. A., Chang, G. J., Feig, B. W., Eng, C., Krishnan, S., Maru, D. M., & Das, P. (2011) · Cancer · doi:10.1002/cncr.25973 · Cited by 65
“Tumor distance from anal verge: Median (range), cm 5 [0–12] 5 [0–12] .”
BackgroundDeng, Y., Zhou, J., Fang, L., Cai, Y., Ke, J., Xie, X., Huang, Y., Huang, M., & Wang, J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.767 · Cited by 62
“Neoadjuvant radiochemotherapy (RCT) followed by total mesorectal excision (TME) has become the standard treatment for locally advanced stages II–III rectal cancer (RC) (using the American Joint Committee on Cancer (AJCC) guidelines) within the last decade (Sauer et al, 2004).”
MethodReirradiation to the pelvis for recurrent rectal cancer
Koom, W. S., Choi, Y., Shim, S. J., Cha, J., Seong, J., Kim, N. K., Nam, K. C., & Keum, K. C. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.23023 · Cited by 69
Reconstruction of Pelvic Exenteration Defects with Anterolateral Thigh–Vastus Lateralis Muscle Flaps
Wong, S. L., Garvey, P. B., Skibber, J. M., & Yu, P. (2009) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e3181b5a40f · Cited by 62
Huang, Y., Huang, Y. J., & Wei, P. (2017) · Medicine · doi:10.1097/md.0000000000008171 · Cited by 62
McGory, M. L., Zingmond, D. S., Sekeris, E., Bastani, R., & Ko, C. Y. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-005-0283-6 · Cited by 62
Shelton, J. W., Waxweiler, T. V., Landry, J., Gao, H., Xu, Y., Wang, L., El-Rayes, B., & Shu, H.-K. G. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.015 · Cited by 62
Kim, Y. W., Kim, N. K., Min, B., Hur, H., Kim, J. S., Kim, J. Y., Sohn, S., & Cho, C.-H. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21166 · Cited by 65
Podda, M., Sylla, P. A., Baiocchi, G. L., Adamina, M., Agnoletti, V., Agresta, F., Ansaloni, L., Arezzo, A., Avenia, N., Biffl, W. L., et al. (2021) · World Journal of Emergency Surgery · doi:10.1186/s13017-021-00378-9 · Cited by 67
Chin, R.-I., Roy, A., Pedersen, K. S., Huang, Y., Hunt, S. R., Glasgow, S. C., Tan, B. R., Wise, P. E., Silviera, M. L., Smith, R. K., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.10.004 · Cited by 64
Cetuximab and chemoradiation for rectal cancer–is the water getting muddy?
Glynne‐Jones, R., Mawdsley, S., & Harrison, M. (2010) · Acta Oncologica · doi:10.3109/02841860903536010 · Cited by 64
“4 Gy/28#/38 days 15% 5 year 74% CA0/ARO/AIO-94 [1] 394 120 hour 5FU infusion 50.”
Impact of Tumor Response on Survival After Radiochemotherapy in Locally Advanced Rectal Carcinoma
Rullier, A., Laurent, C., Capdepont, M., Vendrely, V., Bioulac‐Sage, P., & Rullier, É. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d438b0 · Cited by 67
Shivnani, A. T., Small, W. C., Stryker, S. J., Kiel, K. D., Lim, S. J., Halverson, A. L., & Talamonti, M. (2007) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2006.09.030 · Cited by 60
Gao, Y., Lin, J., An, X., Luo, J.-L., Cai, M.-Y., Cai, P., Kong, L.-H., Liu, G., Tang, J.-H., Chen, G., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.07.021 · Cited by 62
Valentini, V., Paoli, A. D., Gambacorta, M. A., Mantini, G., Ratto, C., Vecchio, F. M., Barbaro, B., Innocente, R., Rossi, C. R., Boz, G., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.01.046 · Cited by 63
Xiang, D.-B., Chen, Z.-T., Wang, D., Li, M.-X., Xie, J.-Y., Zhang, Y., Qing, Y., Li, Z.-P., & Xie, J. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.30 · Cited by 60
One-sided tests in shared frailty models
Claeskens, G., Nguti, R., & Janssen, P. (2007) · Test · doi:10.1007/s11749-006-0023-9 · Cited by 67
Jabbour, S. K., Patel, S., Herman, J. M., Wild, A. T., Nagda, S. N., Altoos, T. A., Tunceroglu, A., Azad, N. S., Gearheart, S., Moss, R. A., et al. (2012) · International Journal of Surgical Oncology · doi:10.1155/2012/891067 · Cited by 60
“The 3DCRT toxicity rates were comparable to the German rectal trial in terms of diarrhea, with a rate of grade ≥3 diarrhea of 12–18% compared to 9% in our 3DCRT group and 3% in the IMRT group [1].”
Bruheim, K., Svartberg, J. B., Carlsen, E., Dueland, S., Haug, E., Skovlund, E., Tveit, K. M., & Guren, M. G. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.10.043 · Cited by 64
Mohiuddin, M., Paulus, R., Mitchell, E. P., Hanna, N. N., Yuen, A., Nichols, R. C., Yalavarthi, S., Hayostek, C. J., & Willett, C. G. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.020 · Cited by 66
Wee, C. W., Kang, H., Wu, H.-G., Chie, E. K., Choi, N., Park, J. M., Kim, J.-I., Huang, C., Wang, J., Ng, S., et al. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy029 · Cited by 62
“Although the rates of acute treatment-related toxicities seem to be reduced due to the shift from adjuvant to the neoadjuvant setting (1), acute toxicity due to NCRT is still a limiting factor for compliance to treatment and the quality of life in patients with LARC (6,7).”
BackgroundSprenger, T., Beißbarth, T., Sauer, R., Tschmelitsch, J., Fietkau, R., Liersch, T., Hohenberger, W., Staib, L., Gaedcke, J., Raab, H.-R., et al. (2018) · British journal of surgery · doi:10.1002/bjs.10877 · Cited by 60
Self-citationSong, J. H., Yu, M., Kang, K. M., Lee, J. H., Kim, S. H., Nam, T., Jeong, J. U., Jang, H. S., Lee, J. W., & Jung, J. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.01.002 · Cited by 60
Martínez, M. C. R., Fernández-Martos, C., Graválos-Castro, C., Espinosa-Olarte, P., Salvia, A. L., Robles-Diaz, L., Modrego-Sánchez, A., & García‐Carbonero, R. (2020) · Cancers · doi:10.3390/cancers12123655 · Cited by 62
Li, M., Xiao, Q., Venkatachalam, N., Hofheinz, R., Veldwijk, M. R., Herskind, C., Ebert, M. P. A., & Zhan, T. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221077972 · Cited by 64
Mantel, F., Frey, B., Haslinger, S., Schildkopf, P., Sieber, R., Ott, O. J., Lödermann, B., Rödel, F., Sauer, R., Fietkau, R., et al. (2010) · Strahlentherapie und Onkologie · doi:10.1007/s00066-010-2154-x · Cited by 62
“Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improves local control of colorectal cancer [ 28 ].”
BackgroundSelf-citationAvallone, A., Aloj, L., Caracò, C., Delrio, P., Pecori, B., Tatangelo, F., Scott, N., Casaretti, R., Gennaro, F. D., Montano, M., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2229-2 · Cited by 60
“Despite these important advances, the rate of occurrence of distant metastases, which still represent the site of failure of approximately one third of patients with LARC, has remained unchanged, underlining the need for a more intensified systemic approach [2, 3].”
BackgroundMethodFemale fertility and colorectal cancer
Spanos, C. P., Mamopoulos, A. M., Τσάπας, Α., Syrakos, T., & Kiskinis, D. (2008) · International Journal of Colorectal Disease · doi:10.1007/s00384-008-0483-3 · Cited by 61
Kikuchi, M., Mikami, T., Sato, T., Tokuyama, W., Araki, K., Watanabe, M., Saigenji, K., & Okayasu, I. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605105 · Cited by 65
“Although in locally advanced cases there is generally no improvement of overall survival, local control is better than with postoperative CRT (Sauer et al, 2004).”
BackgroundValentini, V., Coco, C., Rizzo, G., Manno, A., Crucitti, A., Mattana, C., Ratto, C., Verbo, A., Vecchio, F. M., Barbaro, B., et al. (2009) · Surgery · doi:10.1016/j.surg.2009.01.007 · Cited by 61
Herman, M. P., Kopetz, S., Bhosale, P., Eng, C., Skibber, J. M., Rodrı́guez-Bigas, M. A., Feig, B. W., Chang, G. J., Delclos, M. E., Krishnan, S., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.08.054 · Cited by 59
“More recently, a randomized trial showed that preoperative chemoradiation reduces local recurrence and toxicity compared with postoperative chemoradiation (5).”
BackgroundKusters, M., Holman, F. A., Martijn, H., Nieuwenhuijzen, G. A. P., Creemers, G., Gooszen, A. W., van den Berg, H. A., van den Brule, A. J. C., van de Velde, C. J. �., & Rutten, H. J. T. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.03.002 · Cited by 59
“Still, local recurrence rates vary between 6% and 33%, depending on tumor stage and type of treatment [1–3].”
BackgroundPinto, C., Fabio, F. D., Maiello, E., Pini, S., Latiano, T. P., Aschele, C., Garufi, C., Bochicchio, A. M., Rosati, G., Aprile, G., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq782 · Cited by 63
“In locally advanced rectal cancer (LARC) patients, neoadjuvant preoperative chemoradiation has been shown to increase the pathological complete response (pCR) and locoregional control but has not demonstrated an improvement in overall survival (OS) [1–3].”
BackgroundMetastatic Dormancy Imposed by the Primary Tumor: Does it Exist in Humans?
Peeters, C. F. J. M., de Waal, R. M. W., Wobbes, T., & Ruers, T. J. M. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0029-5 · Cited by 63
Huntington, C. R., Boselli, D. M., Symanowski, J. T., Hill, J. S., Crimaldi, A. J., & Salo, J. C. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4927-z · Cited by 63
“Neoadjuvant therapy prior to surgical resection allows for tumor regression, better local control, and increased rates of sphincter preservation.(1,2) However, the optimal timing of surgery after radiation therapy (radiationsurgery interval) has not been determined.”
BackgroundMethodImpact of multimodal therapy in locally recurrent rectal cancer
You, Y. N., Skibber, J. M., Hu, C.-Y., Crane, C. H., Das, P., Kopetz, S., Eng, C., Feig, B. W., Rodríguez-Bigas, M. A., & Chang, G. J. (2016) · British journal of surgery · doi:10.1002/bjs.10079 · Cited by 59
Do Moderate Surgical Treatment Delays Influence Survival in Colon Cancer?
Wanis, K. N., Patel, S. V., & Brackstone, M. (2017) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000857 · Cited by 59
Valentini, V., Gambacorta, M. A., Cellini, F., Aristei, C., Coco, C., Barbaro, B., Alfieri, S., D’Ugo, D., Persiani, R., Deodato, F., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.11.023 · Cited by 59
“Oxaliplatin is a drug concomitantly applied as a chemosensitiser in LCRCT schedules; it improved clinical outcome and pCR rates in some series [7] although other did not reveal clinical benefit [8,9].”
BackgroundInfluentialPreoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost
Jakobsen, A. K. M., Mortensen, J. P., Bisgaard, C., Lindebjerg, J., Hansen, J. W., & Rafaelsen, S. R. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.07.969 · Cited by 59
Petresc, B., Lebovici, A., Caraiani, C., Feier, D. S., Graur, F., & Buruian, M. M. (2020) · Cancers · doi:10.3390/cancers12071894 · Cited by 62
Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review
Arredondo, J., Pastor, E., Simó, V., Beltrán, M., Castañón, C., Magdaleno, M. C., Matanza, I., Notarnicola, M., & Ielpo, B. (2020) · Techniques in Coloproctology · doi:10.1007/s10151-020-02289-4 · Cited by 63
Perez, R. O., Habr‐Gama, A., Smith, F. M., Kosinski, L. A., Julião, G. P. S., Grzona, E., Rawet, V., Vianna, M. R., Proscurshim, I., Lynn, P. B., et al. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23571 · Cited by 58
“Multimodality neoadjuvant therapy has become the standard of care for locally advanced rectal cancer [1].”
BackgroundCho, Y. B., Chun, H.-K., Kim, M. J., Choi, J. Y., Park, C., Kim, B., Lee, S. J., Yun, S. H., Kim, H. C., & Lee, W. Y. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-0248-3 · Cited by 58
Dahl, O., Fluge, Ø., Carlsen, E., Wiig, J. N., Myrvold, H. E., Vonen, B., Podhorny, N., Bjerkeset, O. A., Eide, T. J., Halvorsen, T. B., et al. (2009) · Acta Oncologica · doi:10.1080/02841860902755244 · Cited by 58
“In a German randomised trial preoperative chemoradiotherapy reduced the local recurrence rate but had no effect on distant recurrence rate compared with postoperative chemoradiotherapy [41].”
BackgroundWho Benefits From Adjuvant Radiation Therapy for Gastric Cancer? A Meta-Analysis
Ohri, N., Garg, M. K., Aparo, S., Kaubisch, A., Tomé, W. A., Kennedy, T. J., Kalnicki, S., & Guha, C. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.008 · Cited by 60
Xu, Z., Shen, F., Li, X., Wu, Y. H., Chen, Q., Xu, J., & Yao, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041137 · Cited by 60
Metadata
- Authors
- Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., & Raab, R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Leipzig University (DE)
- University of Rostock (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital of the Brothers of St. John of God (AT)
- Klinikum Klagenfurt (AT)
- University of Göttingen (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Oldenburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1731-1740
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125452425
- Cited by
- 6,050
- References
- 19
- Citations by year
- 2026: 178 · 2025: 205 · 2024: 232 · 2023: 275 · 2022: 310 · 2021: 324 · 2020: 322 · 2019: 321 · 2018: 305 · 2017: 298 · 2016: 291 · 2015: 348 · 2014: 340 · 2013: 333 · 2012: 346
- FWCI
- 82.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- rectal cancer, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, postoperative chemoradiotherapy, neoadjuvant therapy, adjuvant therapy, 5-fluorouracil, boost radiotherapy, local recurrence, overall survival, treatment toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Postoperative Care, Postoperative Complications, Preoperative Care, Quality Control, Radiotherapy, Rectal Neoplasms, Incidence, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.